Shah Sangam, Paudel Kiran, Bhattarai Abhinav, Thapa Sangharsha, Bhusal Sandesh, Adhikari Yagya R, Adhikari Tara B, Bhatta Nikita, Mandal Prince, Sharma Pratima, Budha Bishal, Aryal Shova, Das Santa K, Pant Pankaj
Institute of Medicine Tribhuvan University Maharajgunj Nepal.
Nepal Health Frontiers Kathmandu Tokha Nepal.
Health Sci Rep. 2023 Sep 25;6(9):e1579. doi: 10.1002/hsr2.1579. eCollection 2023 Sep.
The effectiveness of coronavirus disease 2019 (COVID-19) vaccines in reducing symptoms, disease advancement, complications, and mortality in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been well-established. This case-control study aimed to compare different blood parameters, and prognostic and survival outcomes of COVID-19 patients based on vaccination status.
We performed a case-control study that included hospitalized patients with COVID-19 at Tribhuvan University Teaching Hospital, Kathmandu, Nepal. Individuals who received vaccination were designated as cases and unvaccinated individuals as controls. Demographics, co-morbidity, clinical data, laboratory data, and disease outcomes were recorded for both groups. Multivariate, Cox, and linear regression were used for analysing blood parameters, hospital admission, survival, and hospital stay, respectively, between cases and controls.
Out of 100 participants enrolled, 46 were vaccinated, and 54 weren't. At admission, ferritin and erythrocyte sedimentation rate (ESR) were significantly lower in cases. At discharge, cases showed a higher monocyte than controls. Ferritin, ESR, and d-imer showed excellent performance in determining the severity of symptoms. Significant correlation and regression of ferritin and ESR with the length of hospital stay was observed. Length of hospital stay was significantly lower in cases than in controls. No significant differences between cases and controls were observed in mortality.
COVID-19 vaccines effectively reduced hospitalization duration. Ferritin and ESR were significantly lower in vaccinated individuals and showed the best utility in monitoring the disease.
2019冠状病毒病(COVID-19)疫苗在减轻严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的症状、疾病进展、并发症及降低死亡率方面的有效性已得到充分证实。本病例对照研究旨在比较COVID-19患者基于疫苗接种状况的不同血液参数、预后及生存结果。
我们开展了一项病例对照研究,纳入了尼泊尔加德满都特里布万大学教学医院的COVID-19住院患者。接种疫苗的个体被指定为病例组,未接种疫苗的个体为对照组。记录两组的人口统计学信息、合并症、临床数据、实验室数据及疾病结局。分别采用多变量分析、Cox回归和线性回归分析病例组和对照组之间的血液参数、住院情况、生存情况及住院时间。
在纳入的100名参与者中,46人接种了疫苗,54人未接种。入院时,病例组的铁蛋白和红细胞沉降率(ESR)显著较低。出院时,病例组的单核细胞高于对照组。铁蛋白、ESR和D-二聚体在确定症状严重程度方面表现出色。观察到铁蛋白和ESR与住院时间存在显著相关性及回归关系。病例组的住院时间显著短于对照组。病例组和对照组在死亡率方面未观察到显著差异。
COVID-19疫苗有效缩短了住院时间。接种疫苗个体的铁蛋白和ESR显著较低,在监测疾病方面表现出最佳效用。